8 results

  • avastin

    (bevacizumab)
    Genentech, Inc.
    Avastin is indicated for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent or recurrent cervical cancer, and advanced epithelial ovarian or peritoneal cancers, often in combination with other chemotherapy agents.

  • byooviz

    (ranibizumab-nuna)
    BIOGEN INC.
    BYOOVIZ is indicated for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV) in patients.

  • cimerli

    (ranibizumab-eqrn)
    Coherus BioSciences Inc
    CIMERLI is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

  • eylea hd

    (aflibercept)
    Regeneron Pharmaceuticals, Inc
    EYLEA HD is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).

  • lucentis

    (RANIBIZUMAB)
    Genentech, Inc.
    LUCENTIS is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

  • susvimo

    (Ranibizumab)
    Genentech, Inc.
    SUSVIMO (ranibizumab injection) is indicated for treating patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor.

  • zaltrap

    (ziv-aflibercept)
    sanofi-aventis U.S. LLC
    ZALTRAP, combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after treatment with an oxaliplatin-containing regimen.

  • zirabev

    (bevacizumab-bvzr)
    Pfizer Laboratories Div Pfizer Inc
    ZIRABEV is indicated for treating metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent/recurrent/metastatic cervical cancer, and advanced epithelial ovarian/fallopian tube/peritoneal cancer, often in combination with other chemotherapy agents.